Type 2 Diabetes Market to 2019 - A
Shifting Treatment Algorithm and Intensified Competition Expected to Drive
Growth by 2019
GBI
Research has released its latest report for the pharmaceuticals industry, “Type
2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified
Competition Expected to Drive Growth by 2019”. There is currently a large
number of blood glucose-lowering drugs in the crowded type 2 diabetes market
indicated for the treatment of chronically high blood glucose. The market is
led by Lantus, which achieved global sales amounting to $6.4 billion in 2012.
Over the forecast period from 2012 to 2019, the safer, more efficacious newer
classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are
expected to capture substantial market shares, largely replacing older classes
such as sulfonylureas and thiazolidinediones.
To
Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/type-2-diabetes-market-to-2019-a-shifting-treatment-algorithm-and-intensified-competition-expected-to-drive-growth-by-2019
Additionally,
a variety of novel drugs belonging to these newer classes are due to enter the
market, and are expected to offer a moderate improvement in terms of efficacy
and safety. The price of these new therapies is expected to be high, but this
is unlikely to hinder their uptake. As a result, as well as an overall increase
in the prevalent population, GBI Research believes that the value of the global
market has the potential to grow to reach $38.8 billion by 2019.
Scope
- A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
- In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
- Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers and barriers for market growth
Reasons
to Buy
- Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
- Understand the strengths and weaknesses of each product
- Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.
Table
of Content
1
Table of Contents 1
1.1
List of Tables 5
1.2
List of Figures 6
2
Executive Summary 7
2.1
A Highly Competitive and Growing Market 7
2.2
Strong Pipeline Containing a Diverse Set of Products 8
For
More Information Diabetes Market
Research Reports @:
3
Introduction 9
3.1
Epidemiology 9
3.2
Symptoms 9
3.3
Etiology 10
3.4
Pathophysiology 10
3.5
Co-morbidities and Complications 11
3.6
Classification 12
3.7
Prognosis 13
3.8
Diagnosis 13
3.9
Assessing Treatment Effectiveness 15
3.10
Treatment Algorithm 15
3.10.1
The Role of Insulin in Type 2 Diabetes 17
3.10.2
Non-insulin Diabetic Drugs 18
3.10.3
Other Drugs 20
3.11
GBI Research Report Guidance 20
About
Us
Marketresearchreports.biz
is the most comprehensive collection of market research reports.
Marketresearchreports.biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs,
our main offerings are syndicated research reports, custom research,
subscription access and consulting services. We serve all sizes and types of
companies spanning across various industries.
With a team of
experienced consultants we are committed to serve our clients in a way which
increase their efficiency, reduce costs and saves time. Our professional search
engine helps you in finding the best and latest market research report with
just one click of the mouse. Our database represents the most updates and
latest market research report collections form all the leading market research
publishers across the globe
Contact
M/s Sheela
90 Sate Street, Suite
700
Albany, NY 12207
USA – Canada Toll
Free: 866-997-4948
No comments:
Post a Comment